Category: Drug Safety Alerts
-
Newer Diabetes Drugs Side Effect: Fournier’s Gangrene, Serious Infection Of Genital Area
FDA Mandates Label Changes With New Warnings For Invokana, Farxiga, Jardiance, Other SGLT2 Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In late August 2018 the FDA warned doctors and patients that cases…
-
Invokana / Jardiance / Farxiga: Increased Risks Of Lower-Limb Amputations Compared To Another Class Of Diabetes Drugs
Today Only The Invokana Drug Label Includes Warnings About Amputations Of Legs, Feet, And Toes; Will There Be Label Changes For Farxiga And Jardiance? (Posted by Tom Lamb at DrugInjuryWatch.com) Another new…
-
Diabetes Drug Tradjenta Associated With Bullous Pemphigoid, A Chronic Blistering Skin Condition
Bullous Pemphigoid (BP) Is An Auto-Immune Skin Disease Which Can Be Fatal, Particularly In Patients Who Are Debilitated (Posted by Tom Lamb at DrugInjuryWatch.com) Three relatively new medical studies add weight to…
-
Actemra Side Effects: Pulmonary Hypertension, Interstitial Lung Disease, Pulmonary Alveolar Proteinosis
FDA Watch List Includes Actemra: Evaluating Regulatory Action Based On Possible Signs Of Serious Risk, New Safety Information (Posted by Tom Lamb at DrugInjuryWatch.com) In July 2018 the FDA issued this document,…
-
Bayer: Essure Permanent Birth Control Device Removal From US Market Is “Business Decision”
Or Is This Really An Essure Recall Due To High Numbers Of Adverse Events Reported To FDA And Related Essure Lawsuits (Posted by Tom Lamb at DrugInjuryWatch.com) We have reported developments concerning…
-
Pradaxa-Related Liver Injury: Health Canada’s Drug Safety Review Of Pradaxa Concludes There Is A Link
Remains Unknown Whether Pradaxa Label Change About Liver Damage In Canada Will Be Followed By Similar FDA Action In US (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2018 Health Canada announced…
-
Gadolinium Toxicity Risks Higher For Children, Pregnant Women, And People Receiving Multiple Doses
Gadolinium Deposition Disease And Neurological Adverse Reactions Associated With The Use Of Gadolinium-Based Contrast Agents (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2018 Health Canada announced the results of its second…
-
Gout Drug Uloric Recall By FDA Requested In June 2018 Public Citizen Petition Letter
Consumer Group Contends That The Evidence Of Harmful Uloric Side Effects Outweighs Any Real Benefit To Patients (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA should order Takeda Pharmaceuticals to immediately withdraw from…
-
Gadolinium Retention Warnings Added To Drug Labels For Gadolinium Contrast Agents Used During MRI / MRA
Label Changes Announced By FDA In December 2017 Finally Approved For Magnevist, Omniscan, And Other GBCAs In April 2018 (Posted by Tom Lamb at DrugInjuryWatch.com) Gadolinium based contrast agents (GBCAs) are substances…
-
Some MRI Contrast Agents Containing Gadolinium Can Cause Problems Ranging From “Brain Fog” To Permanent Disability
Gadolinium Deposition Disease Symptoms Typically Begin Couple Of Months After Use And Can Continue For Many Years Without Any Diagnosis (Posted by Tom Lamb at DrugInjuryWatch.com) During MRI and MRA procedures patients…